Prostate cancer showdown: surgery vs. radiation – which works better?
NCT ID NCT07205783
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at 40 men with early-stage prostate cancer to compare two standard treatments: open surgery to remove the prostate and radiation therapy. The goal is to see which approach better controls the tumor and prevents recurrence. The results may help guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors choose the best treatment for early-stage prostate cancer.
- What could go wrong
- This is a small, retrospective study with only 40 participants, so results may not apply to everyone. It compares existing treatments, not a new breakthrough.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2022
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Cancer prostate: confirmed by prostate biopsy Cancer stage: T2,T3 Exclusion Criteria: * coagulopathy. Pulmonary diseases metastatic tumor
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sohag University
Sohag, 82511, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- RE-irradiation for isolated FOCal recurrence of prostate cancer with ultrahypofracted SBRT: the RE-FOCUS study - pushing the boundaries of precision and efficacy
- A sharper eye for cancer: new PET tracer targets hidden tumors
- Can a radioactive tracer help surgeons find hidden prostate cancer?
- Steam therapy vs. surgery: can a less invasive fix help men with blocked urine flow?
- Can smart fluid monitoring improve robotic prostatectomy outcomes?
- Smart blood pressure monitoring may shield kidneys during robotic surgery